Last reviewed · How we verify
Tamiflu®
Tamiflu inhibits viral neuraminidase, preventing influenza virus particles from being released from infected cells.
Tamiflu inhibits viral neuraminidase, preventing influenza virus particles from being released from infected cells. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.
At a glance
| Generic name | Tamiflu® |
|---|---|
| Sponsor | Genuine Research Center, Egypt |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir (Tamiflu) is a prodrug that is converted to its active form in the body. The active metabolite binds to and inhibits influenza neuraminidase, an enzyme on the viral surface that cleaves sialic acid receptors. By blocking this enzyme, the drug prevents newly formed virus particles from escaping infected cells and spreading to uninfected cells, thereby reducing viral replication and shortening illness duration.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age
- Prophylaxis of influenza A and B in patients ≥1 year of age
Common side effects
- Nausea
- Vomiting
- Headache
- Abdominal pain
Key clinical trials
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza (PHASE2)
- Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers (PHASE4)
- Test-and-treat for Influenza in Homeless Shelters (PHASE4)
- Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children (NA)
- Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia (PHASE3)
- Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (PHASE3)
- Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit (NA)
- A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |